Navigation Links
Peptimmune Files Citizen Petition Regarding Generic Copaxone and Demonstrates Significant Enabling Technology for Biological Characterization of Copaxone
Date:10/4/2010

ce for a generic copy of Copaxone should include the comparative PK and PD studies proposed in the Citizen Petition.  Our studies demonstrate a direct correlation between Copaxone serum exposure and activation of the innate immune system.  Controlling this relationship in particular is critical to ensure safety and therapeutic effect of any generic copy of Copaxone.  The effect of Copaxone cannot just be simply explained by induction of regulatory T cells; its effect on antigen presenting cells is just as important.  Systemic exposure of Copaxone facilitates the direct effect on monocyte activity, perhaps even in the brain.  If a generic manufacturer primarily limits its characterization of a generic copy to comparative antibody responses or T cell responses they could be significantly underestimating the copy's biological effects."

The Citizen Petition is available for download at www.peptimmune.com/news.

About Multiple Sclerosis

Over 400,000 Americans have multiple sclerosis (MS), and MS may affect over 2.5 million individuals worldwide.  MS is an autoimmune disease in which the individual's immune system responds against multiple components of nerve-insulating myelin.  The effects of these immune-mediated attacks can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.

About Peptimmune

Peptimmune, Inc. is a privately held clinical stage biotechnology company focused on the development of PI-2301, a second-generation peptide copolymer from a similar compound class as Copaxone. PI-2301 has shown to be more potent and effective than Copaxone in treating disease models for multiple sclerosis. The Company plans to continue developing this promising compound by initiating a Phase II study in relapsing remitting multiple sclerosis patients later this y
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
2. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
4. Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
5. Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
6. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
7. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
8. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
9. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... ANDOVER, Mass. , July 24, 2014   ... pulmonary function testing (PFT) employing precise ultrasound technology, announced ... as the instrument to measure Carbon Monoxide Diffusing Capacity ... Study, the most comprehensive study of Chronic Obstructive Pulmonary ... leading cause of death in the U.S. and affects ...
(Date:7/24/2014)... and VANCOUVER, British Columbia ... (NASDAQ: OGXI ) announced today that the ... on Thursday, August 7, 2014, and that the Company ... 4:30 p.m. ET that afternoon. Management will provide an ... a general business update. To access ...
(Date:7/23/2014)... Australia , July 24, 2014 ... Melbourne , the agreement seeks to increase access ... At the AIDS 2014 conference in ... a new licensing agreement with Gilead Sciences for tenofovir alafenamide ... The licence will allow manufacturers in India ...
Breaking Medicine Technology:EasyOne Pro from ndd Medical Technologies Chosen Again as the Exclusive PFT Testing Technology in Phase 2 of COPDGene Study 2OncoGenex to Report Financial Results for Second Quarter 2014 on August 7, 2014 2The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 2The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 3
... Medical has been at the cutting edge of ... famous Resusci Anne in 1960. Fifty years on, ... launches its latest SimMan patient simulator, SimMan® Essential. ... (Photo: http://www.newscom.com/cgi-bin/prnh/20100830/NY56743 ) ...
... accelerating pace of scientific discovery in life sciences, coupled ... of genetic information, the field of personalized medicine has ... predictive and preventative care utilizing diagnostics that allow physicians ... therapeutic regimes are most effective, and determine long-term susceptibility ...
Cached Medicine Technology:Laerdal Introduces SimMan Essential 2Laerdal Introduces SimMan Essential 3Personalized Medicine: Conference Provides Update on Progress and Prospects 2
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 On October ... ones will descend upon the Embassy Suites LAX North for ... hosted by DiabetesSisters and the first time it has convened ... time for the organization to open the entire event to ... the only conference of its kind worldwide for women with ...
(Date:7/24/2014)... July 24, 2014 (HealthDay News) -- A new formulation ... from snorting or injecting the drug has been approved ... Targiniq ER and made by Purdue Pharma, the pill ... a drug that blocks the euphoric effects of oxycodone. ... crushed, snorted, dissolved or injected, according to the FDA. ...
(Date:7/24/2014)... 24, 2014 Skirt Sports, the innovative women’s ... of the running skirt. Born from an idea by professional ... an Ironman race in 2004, this one innovative piece of ... prize money from her victory in Wisconsin to incorporate Skirt ... specific athletic skirts. , “When I drew the first sketch ...
(Date:7/24/2014)... July 24, 2014 The North American Omega ... omega 3 & structured lipids market in North America with ... is estimated to grow from around $762.4 million in 2012 ... from 2013 to 2018. , Browse through the TOC of ... to get an idea of the in-depth analysis provided. This ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... to announce a new distribution agreement with game ... collaboration between the two groups to offer ... clinicians using biofeedback and neurofeedback in European and ... “video game” developed expressly to be used as ...
Breaking Medicine News(10 mins):Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 2Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 3Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:Skirt Sports Celebrates Its 10-Year Anniversary and 10 Years of the Running Skirt With a Virtual Community Building Run 2Health News:Skirt Sports Celebrates Its 10-Year Anniversary and 10 Years of the Running Skirt With a Virtual Community Building Run 3Health News:North America Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $1,117 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $1,117 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $1,117 million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $1,117 million in 2018 - New Report by MicroMarket Monitor 5Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 2Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 3
... are seeing the first signs of a reverse brain ... grow over time. The emergence of modern,corporate and investorowned ... NRI doctors back to home turf. ,And unlike other ... the main draw, doctors are actually taking pay cuts ...
... together will build the worlds first "all digital ... by the out patient surgical rehabilitation chain. The ... screens connected to the Internet, electronic medical records ... permitting doctors and other caregivers to access patients' ...
... in the United States of America, says that children suffer ... an unhappy marriage and avoid a divorce for the sake ... only do more damage to the kids, the authors of ... of Pennsylvania State University in University Park conducted the exhaustive ...
... giants has just begun. After waging wars over many drug ... treatment. The ball was set in motion by the dramatic ... AIDS treatment would cost less than a U.S. dollar a ... announced plans of its own production of anti retroviral drugs ...
... humour. It stirred up a controversy. Now it is being ... officially announced that the advertisement in question might not be ... they did not enjoy the advertisement poking fun at organ ... a carousel horse. A team of medics approaches him and ...
... the tedious process of finding survivors of the Gujarat quake, from ... more survivors. They are now concentrating in clearing the rubble and ... far. A miracle baby was saved after nearly 90 hours under ... holding on to the dead body of its mother. The baby ...
Cached Medicine News:Health News:Lure of the home turf brings back NRI doctors 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: